Preclinical, randomized phase 1, and compassionate use evaluation of REGN4461, a leptin receptor agonist antibody for leptin deficiency
Judith Y Altarejos,Jeffrey Pangilinan,Simona Podgrabinska,Baris Akinci,Maria Foss-Freitas,Adam H Neidert,Yonaton Ray,Wenjun Zheng,Steven Kim,Vishal Kamat,Meilin Huang,Soo Min,Jason Mastaitis,Giselle Dominguez-Gutierrez,Jee-Hae Kim,Panayiotis Stevis,Tammy Huang,Brian Zambrowicz,William C Olson,Stephen Godin,Elizabeth Bradley,Andrew D Gewitz,Mark Baker,Rita Hench,Matthew S Davenport,Thomas L Chenevert,Frank DiPaola,George D Yancopoulos,Andrew J Murphy,Gary A Herman,Bret J Musser,Hayes Dansky,Joyce Harp,Jesper Gromada,Mark W Sleeman,Elif A Oral,Benjamin A Olenchock
DOI: https://doi.org/10.1126/scitranslmed.add4897
2023-11-22
Abstract:Deficiency in the adipose-derived hormone leptin or leptin receptor signaling causes class 3 obesity in individuals with genetic loss-of-function mutations in leptin or its receptor LEPR and metabolic and liver disease in individuals with hypoleptinemia secondary to lipoatrophy such as in individuals with generalized lipodystrophy. Therapies that restore leptin-LEPR signaling may resolve these metabolic sequelae. We developed a fully human monoclonal antibody (mAb), REGN4461 (mibavademab), that activates the human LEPR in the absence or presence of leptin. In obese leptin knockout mice, REGN4461 normalized body weight, food intake, blood glucose, and insulin sensitivity. In a mouse model of generalized lipodystrophy, REGN4461 alleviated hyperphagia, hyperglycemia, insulin resistance, dyslipidemia, and hepatic steatosis. In a phase 1, randomized, double-blind, placebo-controlled two-part study, REGN4461 was well tolerated with an acceptable safety profile. Treatment of individuals with overweight or obesity with REGN4461 decreased body weight over 12 weeks in those with low circulating leptin concentrations (<8 ng/ml) but had no effect on body weight in individuals with higher baseline leptin. Furthermore, compassionate-use treatment of a single patient with atypical partial lipodystrophy and a history of undetectable leptin concentrations associated with neutralizing antibodies to metreleptin was associated with noteable improvements in circulating triglycerides and hepatic steatosis. Collectively, these translational data unveil an agonist LEPR mAb that may provide clinical benefit in disorders associated with relatively low leptin concentrations.